Artiva Biotherapeutics, Inc. (37)

Browse by Contract Category

Contracts

First Amendment to License Agreement, dated May 9, 2022, by and between the Registrant and ARE-SD Region No. 37, LLC (Filed With SEC on June 6, 2022)
Employment Offer Letter, dated May 21, 2022, by and between the Registrant and Thorsten Graef, M.D., Ph.D (Filed With SEC on June 6, 2022)
Omnibus Amendment, dated February 3, 2022, by and between the Registrant and GC Cell Corporation (Filed With SEC on March 7, 2022)
Filing Fee Disclosure and Payment Methods (Note: To be filed as Exhibit 107 but encountered hyperlink issues) (Filed With SEC on January 21, 2022)
Amendment No. 1 to Strategic Collaboration Agreement, dated October 18, 2021, by and between the Registrant and Affimed GmbH (Filed With SEC on December 16, 2021)
Office Lease, dated June 12, 2019, by and between the Registrant and AAT La Jolla Commons, LLC (as successor-in-interest to HSPF La Jolla Commons I Investors LLC) (Filed With SEC on April 8, 2021)
Consulting Agreement, dated December 15, 2020, by and between the Registrant and Fred Aslan, M.D (Filed With SEC on January 21, 2022)
Employment Offer Letter, dated December 7, 2021, by and between the Registrant and Christopher P. Horan (Filed With SEC on January 21, 2022)
Retention Agreement, dated September 21, 2021, by and between the Registrant and Dr. Jason Litten (Filed With SEC on January 21, 2022)
Form of Underwriting Agreement (Filed With SEC on January 21, 2022)
Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the Artiva Biotherapeutics, Inc. 2022 Equity Incentive Plan (Filed With SEC on December 16, 2021)
Form of Common Stock Certificate (Filed With SEC on December 16, 2021)
Artiva Biotherapeutics, Inc. 2022 Equity Incentive Plan (Filed With SEC on December 16, 2021)
Artiva Biotherapeutics, Inc. 2022 Employee Stock Purchase Plan (Filed With SEC on December 16, 2021)
Non-Employee Director Compensation Policy (Filed With SEC on December 16, 2021)
Separation Agreement, dated October 15, 2021, by and between the Registrant and Thomas J. Farrell (Filed With SEC on December 16, 2021)
Merck Partnered Product Research Services and License Agreement, dated January 27, 2021, by and between the Registrant and Green Cross LabCell Corporation (Filed With SEC on April 8, 2021)
Selected Product License Agreement (AB-202), dated March 24, 2021, by and between the Registrant and Green Cross LabCell Corporation (Filed With SEC on April 8, 2021)
Strategic Collaboration Agreement, dated November 5, 2020, by and between the Company and Affimed GmbH (Filed With SEC on April 8, 2021)
Amended and Restated Investors Rights Agreement, dated February 22, 2021, by and among the Registrant and certain of its stockholders (Filed With SEC on April 8, 2021)
Form of Indemnification Agreement by and between the Registrant and its directors and officers (Filed With SEC on April 8, 2021)
Employment Offer Letter, dated August 24, 2020, as amended, by and between the Registrant and Jennifer Bush (Filed With SEC on April 8, 2021)
Artiva Biotherapeutics, Inc. 2020 Equity Incentive Plan, as amended (Filed With SEC on April 8, 2021)
Forms of Stock Option Grant Notice, Stock Option Grant Notice with Acceleration of Vesting, Option Agreement and Notice of Exercise under the Artiva Biotherapeutics, Inc. 2020... (Filed With SEC on April 8, 2021)
Executive Employment Agreement, dated December 14, 2020, as amended, by and between the Registrant and Fred Aslan, M.D (Filed With SEC on April 8, 2021)
Executive Employment Agreement, dated March 1, 2019, as amended, by and between the Registrant and Thomas J. Farrell (Filed With SEC on April 8, 2021)
Employment Offer Letter, dated March 16, 2019, as amended, by and between the Registrant and Dr. Peter Flynn (Filed With SEC on April 8, 2021)
Employment Offer Letter, dated August 11, 2019, as amended, by and between the Registrant and Dr. Jason Litten (Filed With SEC on April 8, 2021)
Employment Offer Letter, dated March 22, 2021, by and between the Registrant and Michael E. Faerm (Filed With SEC on April 8, 2021)
Selected Product License Agreement (AB-201), dated September 29, 2020, by and between the Registrant and Green Cross LabCell Corporation (Filed With SEC on April 8, 2021)
Option and License Agreement, dated September 4, 2019, by and between the Registrant and Green Cross LabCell Corporation (Filed With SEC on April 8, 2021)
Amendment No. 1 to Option and License Agreement, dated June 23, 2020, by and between the Registrant and Green Cross LabCell Corporation (Filed With SEC on April 8, 2021)
Master Agreement for Manufacturing Services, dated March 16, 2020, by and between the Registrant and Green Cross Cell Corporation (Filed With SEC on April 8, 2021)
Amendment No. 1 to Master Agreement for Manufacturing Services, dated June 16, 2020, by and between the Registrant and Green Cross Cell Corporation (Filed With SEC on April 8, 2021)
Master Research Services Agreement, dated August 3, 2020, by and between the Registrant and Green Cross LabCell Corporation (Filed With SEC on April 8, 2021)
Selected Product License Agreement (AB-101), dated November 21, 2019, by and between the Registrant and Green Cross LabCell Corporation (Filed With SEC on April 8, 2021)
Exclusive License and Collaboration Agreement, dated January 27, 2021, by and between the Registrant and Merck Sharp & Dohme Corp (Filed With SEC on April 8, 2021)